Please login to the form below

Not currently logged in
Email:
Password:

Celgene poaches Sanofi Pasteur’s medical director

Adrian Kilcoyne announced as David Gillen’s replacement

Dr Adrian Kilcoyne has left his role as UK medical director at Sanofi Pasteur to join Celgene in the same role.

Taking on his new position this week, Dr Kilcoyne replaces Dr David Gillen who is promoted to head of global drug safety and risk management at Celgene.

He had been UK medical director at Sanofi's vaccines business Sanofi Pasteur since 2011, having joined the company from Roche where he was also medical director.

Other former roles include medical director at Baxter Healthcare and senior clinical research physician at Lilly.

This position at Lilly – which he took on in 2006 – was the first step in Dr Kilcoyne's pharma career and followed several years in primary and secondary care, as well as a spell as a specialist registrar in public health medicines at the Oxford Deanery.

Celgene's general manager for the UK Sam Pearce said: “He brings with him a wealth of experience that will prove a significant addition to the team, enabling us to continue to build on the already great work we are doing."

12th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics